tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Sihuan Pharmaceutical Reports Strong Revenue Growth in H1 2025

Story Highlights
Sihuan Pharmaceutical Reports Strong Revenue Growth in H1 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).

Sihuan Pharmaceutical Holdings Group Ltd. reported a 20.7% increase in total revenue for the first half of 2025, driven by substantial growth in its medical aesthetics business, which saw an 81.3% rise due to strategic expansions and marketing upgrades. While the generic medicine segment experienced a decline, the innovative medicine sector showed a significant increase, contributing to an overall gross profit margin improvement to 66.1%. The company’s R&D expenses decreased as core projects reached commercial application, indicating a shift towards a more profitable phase.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group Ltd. is a company incorporated in Bermuda, operating in the pharmaceutical industry. It focuses on medical aesthetics, generic medicine, and innovative medicine, with a significant market presence in China.

Average Trading Volume: 116,308,087

Technical Sentiment Signal: Buy

Current Market Cap: HK$13.25B

Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1